Protection From SARS-CoV-2 Infection With an Oral Nosode (BiosimCovex): A Randomized, Double-Blind,...

Area of Science:

• Homeopathy
• Immunology
• Infectious Diseases

Background:

• Investigated a potentized, oral homeopathic SARS-CoV-2 nosode (BiosimCovex) for safety, efficacy, and immunogenicity against COVID-19.
• Assessed the potential of homeopathic treatments in managing viral infections.

Purpose of the Study:

• To evaluate the safety, efficacy, and immunogenicity of BiosimCovex against SARS-CoV-2 infection.
• To determine the preventive potential of an oral homeopathic nosode in a large-scale clinical trial.

Main Methods:

• Phase III, multicentre, randomized, double-blind, placebo-controlled trial with 2671 unvaccinated participants.
• BiosimCovex or placebo administered over 3 days; efficacy assessed by RT-PCR, immunogenicity by antibody conversion, and safety via symptom questionnaires.
• Efficacy defined as 100 x (1-IRR), with safety and illness burden monitored throughout the 60-day study.

Main Results:

• Maximum efficacy of 50.06% observed at day 45, higher in females (61.57%) and 18-40 year olds (71.88%).
• Significant antibody conversion (48.4% vs 13.4%, P < 0.001) and reduced symptom duration (P = 0.0085) in the treatment group.
• The homeopathic nosode was found to be safe with mild adverse events resolving without sequelae.

Conclusions:

• A potentized oral nosode (BiosimCovex) demonstrated safety, immunogenicity, and preventive efficacy against SARS-CoV-2 infection over 60 days.
• Effectiveness was notably higher in specific demographics, suggesting targeted potential.
• The study supports the investigation of homeopathic interventions for viral infections.